104 related articles for article (PubMed ID: 11702749)
1. New hope in tipranavir. New Boehringer-Ingelheim protease inhibitor may succeed where others fall short.
Rodriguez E
Posit Living; 2001; 10(6):15. PubMed ID: 11702749
[No Abstract] [Full Text] [Related]
2. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
3. Anti-HIV agents. Tipranavir for treatment-experienced PHAs.
TreatmentUpdate; 2007 Jan; 19(1):8. PubMed ID: 17390481
[No Abstract] [Full Text] [Related]
4. [Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():44-5. PubMed ID: 16385873
[No Abstract] [Full Text] [Related]
5. Tipranavir gets approved.
AIDS Patient Care STDS; 2005 Sep; 19(9):615-6. PubMed ID: 16245408
[No Abstract] [Full Text] [Related]
6. Tipranavir reduces viral load.
AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412583
[No Abstract] [Full Text] [Related]
7. The RESIST trials--superiority of tipranavir over other PIs.
Gonzalez-Lahoz J
AIDS Rev; 2004; 6(4):244-5. PubMed ID: 15793936
[No Abstract] [Full Text] [Related]
8. [New protease inhibitor for PI pretreated patients. Tipranavir targets also multiresistant viruses].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():60-1. PubMed ID: 15373052
[No Abstract] [Full Text] [Related]
9. Tipranavir (Aptivus) for HIV.
Med Lett Drugs Ther; 2005 Oct; 47(1219):83-4. PubMed ID: 16247341
[TBL] [Abstract][Full Text] [Related]
10. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
[No Abstract] [Full Text] [Related]
11. FDA approval: tipranavir.
Sax PE
AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
[No Abstract] [Full Text] [Related]
12. Anti-HIV agents. Unexpected results from a tipranavir study.
TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
[No Abstract] [Full Text] [Related]
13. New protease inhibitor offers clinicians hope for better salvage therapy.
Murphy MJ
HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
[No Abstract] [Full Text] [Related]
14. Tipranavir in the protease inhibitors arena.
Vergani B; Rusconi S
Drugs R D; 2011 Dec; 11(4):291-3. PubMed ID: 22133386
[No Abstract] [Full Text] [Related]
15. FDA approves tipranavir.
IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
[No Abstract] [Full Text] [Related]
16. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2007 Jan; 21(2):179-85. PubMed ID: 17197808
[TBL] [Abstract][Full Text] [Related]
17. Tipranavir: new drug. HIV protease inhibitor. A last resort.
Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
[TBL] [Abstract][Full Text] [Related]
18. New black box warning for ritonavir-boosted tipranavir.
Ryan CT
AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
[No Abstract] [Full Text] [Related]
19. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
20. New therapy for advanced HIV.
FDA Consum; 2005; 39(5):5. PubMed ID: 16419282
[No Abstract] [Full Text] [Related]
[Next] [New Search]
